Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will March 2012 Mark The End Of Regulatory Limbo For Discovery's Surfaxin?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has set a March 6 user fee date for action on Discovery Laboratories' synthetic surfactant, which was filed with the agency in 2004 but is now in its fifth review cycle.

You may also be interested in...



For Discovery’s Surfaxin, Another Delay

Discovery Labs delays the commercial launch of its RDS drug Surfaxin until 2Q 2013, but continues to look for an international partner for the rest of its pipeline. The company assures investors that the delay is not indicative or safety or efficacy problems.

Discovery Labs Admits Pricing For Long-Awaited Surfaxin Will Be Tricky

Surfaxin, a synthetic alternative to animal-derived products for respiratory distress syndrome, deserves a premium, say execs, but company’s main goal is to get top spot on hospital formularies in competition with low-cost rivals.

Pharma Industry Pushes A Broadened Meaning For “Orphan”

BOSTON – Along with the surge in interest in drugs to treat rare or orphan diseases, there has been an increasingly strategic view of what qualifies as an orphan market, with companies looking to subdivide conditions to capitalize on the perceived advantages afforded by rare diseases, according to participants at the recent BioPharm America conference.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel